GENZYME - THE KING OF THE BIOTECHS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert Holmes who wrote (300)	7/26/1998 8:42:00 PM
From: Caveat Emptor	Read Replies (1) of 410

I did find find one answer..ATRAGEN-ARONEX and Geoff Cox... Re: 10Q - Aronex Pharmaceuticals, Inc - Texas aronex.com ..." In September of 1993, the company entered into a collaboration agreement with GENZYME relating to the development and commercialization of ATRAGEN, in connection with which the received net proceeds of approx. $4.5 Million from the sale of common stock to Genzyme..." Geoffrey Cox joined Aronex Pharmaceuticals as Chairman and CEO in October 1997. Cox served most recently at Genzymes Executive Vice President responsible for operations and the Pharmaceutical and diagnostics business units. PROFIT TAKING - GEOFFREY COX - GENZYME SHARES Re: Yahoo Finance Insider Trading Report 9/3/97 - 9/5/97 Sold over 130,000 shares - gross $3.9+ Million 12/4/97 - 12/8/97 Sold over 11,000 shares 1/2/98 - Sold 14,000 Shares - Gross $385,000 shares 1/20/98 Exercised 23,371 Shares Its just that Mr. Cox sold a tremendous amount of stock (along with other officers who remained) during this 3 month window of time. COMPENSATION is my point. You can put as much weight as you want on this information. "INFORMATION IS THE INVESTORS ADVOCATE" CAVEAT EMPTOR

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next